**Author Information** An event is serious (FDA MedWatch definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* requires intervention to prevent permanent impairment or damage

In a report, a 51-year-old man developed fever and rigours and a 43-year-old man developed deterioration Ebola virus disease (EVD) during therapy with Tkm-ebola \[TKM-100802; *route not stated*\].

Patient 1, a 51-year-old man, who had been diagnosed with EVD, received Tkm-ebola infusion at a dose of 0.3 mg/kg on the day 8 of illness. Subsequently, he received the infusion daily for the next 6 day. Later, he received 0.4 mg/kg on illness day 9 and 0.5 mg/kg on illness days 10--14. After the 3 infusions, he developed fever and rigours after 30 minutes, 2.5 hours and 5 hours after infusion, respectively. After the seventh infusion, he experienced rigours. He received total parenteral nutrition on day 10 of illness. Later, his clinical status gradually improved.

Patient 2, a 43-year-old man, who had been diagnosed with EVD, received Tkm-ebola infusion at a dose of 0.3 mg/kg on the day 3 of illness. Subsequently, he received 0.4 mg/kg on day 4 and 0.5 mg/kg on days 5--8. He was suspected for lipaemia, which worsened during the initial days of his hospitalisation. On day 6 of EVD, he developed gastroenteritis and hepatitis and producing approximately 10L of stool in a 24-hour period. He was treated with loperamide and stool output decreased. His stool testing showed the presence of enteropathogenic *Escherichia coli*, which was treated with ceftriaxone. On day 8 of EVD, he developed oliguric acute kidney injury (AKI) with muddy-brown casts in urine sediment, which were most likely secondary to acute tubular necrosis. On day 11, he showed elevated creatinine level. He developed progressive hypoxic acute respiratory failure, and he received invasive mechanical ventilation starting on day 9. His chest radiography findings were consistent with acute respiratory distress syndrome (ARDS). After the fifth dose, his Tkm-ebola therapy was withdrawn due to concern that the therapy was contributing to his overall clinical deterioration. He showed worsening metabolic acidosis and atrial fibrillation with rapid ventricular response which was managed with amiodarone. On day 11, he received continuous renal replacement therapy with transient vasopressor support. He also received convalescent plasma from a recovered EVD patients on days 8, 9, 11, 12, 14, and 15. During initial transfusion, he developed shortness of breath, AKI and ARDS, which required intubation. On day 13, his ceftriaxone therapy was switched to meropenem due to concerns for enteric bacterial translocation and sepsis. His respiratory condition improved and he was extubated on day 21. He remained delirious until day 30. Later, he showed renal recovery and his dialysis was stopped. On day 44, he was discharged in recovered condition with sequelae, which included difficulty ambulating, word-finding difficulties, generalised deconditioning, proximal muscle weakness and residual left shoulder capsulitis.

**Author comment:** *\"The deteriorating clinical course of patient 2 was attributed to EVD, but the possibility that the experimental treatments played some role cannot be excluded.\" \"Patient 1 completed 7 days of TKM-100802 and experienced fever and rigors, which are not unexpected adverse events with an siRNA product.\"*
